We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+8.94%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$76.2B
AUM Growth
+$2.6B
(+3.5%)
Cap. Flow
-$2.97B
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
21.61%
Holding
3,238
New
235
Increased
684
Reduced
2,065
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$77.3M |
| 2 |
Blackstone
BX
|
+$53.2M |
| 3 |
NXP Semiconductors
NXPI
|
+$40.8M |
| 4 |
Palantir
PLTR
|
+$34.3M |
| 5 |
Snowflake
SNOW
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$206M |
| 2 |
Microsoft
MSFT
|
+$163M |
| 3 |
Linde
LIN
|
+$133M |
| 4 |
Amazon
AMZN
|
+$94.7M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$82.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.34% |
| 2 | Financials | 14.16% |
| 3 | Healthcare | 12.95% |
| 4 | Consumer Discretionary | 12.06% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2426
Shattuck Labs
STTK
$694M
| $673K | ﹤0.01% |
23,212
+9,967
| +75% | +$291K |
|
2427
Curis
CRIS
$7.83M
| $672K | ﹤0.01% |
+208
| New | +$940K |
|
|
ITOS
2428
DELISTED
iTeos Therapeutics
ITOS
| $671K | ﹤0.01% |
26,160
+7,594
| +41% | +$181K |
|
2429
Verastem
VSTM
$592M
| $665K | ﹤0.01% |
13,622
-3,148
| -19% | -$131K |
|
|
VLDR
2430
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $665K | ﹤0.01% |
+62,455
| New | +$737K |
|
2431
Coursera
COUR
$1.54B
| $651K | ﹤0.01% |
+16,445
| New | +$707K |
|
2432
Merchants Bancorp
MBIN
$2.49B
| $650K | ﹤0.01% |
24,861
-1,349
| -5% | -$37.4K |
|
|
SCU
2433
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $650K | ﹤0.01% |
26,421
+26
| +0.1% | +$626 |
|
|
MSP
2434
DELISTED
Datto Holding Corp.
MSP
| $650K | ﹤0.01% |
23,351
+3,110
| +15% | +$79.8K |
|
|
REVG
2435
DELISTED
REV Group
REVG
| $649K | ﹤0.01% |
41,341
-3,583
| -8% | -$64.9K |
|
|
SPNE
2436
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $649K | ﹤0.01% |
31,626
-5,623
| -15% | -$116K |
|
2437
NRC Health Common Stock
NRC
$450M
| $646K | ﹤0.01% |
14,067
-1,031
| -7% | -$49K |
|
|
XENT
2438
DELISTED
Intersect ENT, Inc
XENT
| $644K | ﹤0.01% |
37,654
-2,930
| -7% | -$54.8K |
|
|
ETWO
2439
DELISTED
E2open Parent Holdings
ETWO
| $643K | ﹤0.01% |
+56,297
| New | +$648K |
|
2440
Astronics
ATRO
$3.84B
| $641K | ﹤0.01% |
43,958
-3,284
| -7% | -$47.6K |
|
2441
Precigen
PGEN
$2.59B
| $641K | ﹤0.01% |
98,358
+8,597
| +10% | +$60.1K |
|
|
PRVB
2442
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $641K | ﹤0.01% |
76,077
+21,338
| +39% | +$172K |
|
|
IGMS
2443
DELISTED
IGM Biosciences
IGMS
| $640K | ﹤0.01% |
7,695
+40
| +0.5% | +$2.96K |
|
2444
Viking Therapeutics
VKTX
$4B
| $636K | ﹤0.01% |
106,150
-8,601
| -7% | -$51.1K |
|
|
VBIV
2445
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $636K | ﹤0.01% |
6,330
-574
| -8% | -$55.9K |
|
|
BFX
2446
DELISTED
BowFlex Inc.
BFX
| $636K | ﹤0.01% |
37,719
-8,557
| -18% | -$144K |
|
2447
Standard BioTools
LAB
$314M
| $635K | ﹤0.01% |
103,092
-10,201
| -9% | -$54.5K |
|
2448
Pliant Therapeutics
PLRX
$65M
| $634K | ﹤0.01% |
21,765
-2,282
| -9% | -$71K |
|
2449
Crinetics Pharmaceuticals
CRNX
$8.92B
| $632K | ﹤0.01% |
33,551
+5,154
| +18% | +$90.6K |
|
2450
Hovnanian Enterprises
HOV
$807M
| $632K | ﹤0.01% |
+5,946
| New | +$691K |
|
Similar funds
VAM
RhumbLine Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, RhumbLine Advisers held 3,238 positions worth $76.2B, up 3.5% from $73.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
RhumbLine Advisers withdrew a net $2.97B in Q2 2021, closing 243 positions and reducing 2,065 holdings. Its most notable exit was Varian Medical Systems, Inc., an estimated $32.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
Against the trend, RhumbLine Advisers opened a new position in DraftKings worth $14.2M.
- RhumbLine Advisers's largest Q2 2021 buy was DraftKings: 271,227 shares worth $14.2M.
- RhumbLine Advisers added most to iShares Core S&P 500 ETF in Q2 2021, an estimated $77.3M increase.
- RhumbLine Advisers's biggest Q2 2021 reduction was Apple, cutting an estimated $206M.
- RhumbLine Advisers fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $32.1M.
- RhumbLine Advisers's ten largest holdings make up 22% of its $76.2B portfolio in Q2 2021.
- RhumbLine Advisers opened 235 new positions and closed 243 in Q2 2021.
- RhumbLine Advisers's portfolio value rose 3.5% quarter-over-quarter to $76.2B.
Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.